Taxpayers are subsidizing 80 percent of Regeneron’s COVID-19 treatment’s R&D costs
Warning: call_user_func_array() expects parameter 1 to be a valid callback, function 'wp_embed_excerpt_more' not found or invalid function name in /home/keionli38/public_html/wp-includes/class-wp-hook.php on line 341
Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent…